Attached files
| file | filename |
|---|---|
| 8-K/A - THERALINK TECHNOLOGIES, INC. | form8-ka.htm |
March 16, 2017
U.S. Securities and Exchange Commission
Office of the Chief Accountant
100F Street Northeast
Washington, DC 20549-2000
| RE: | ONCBIOMUNE PHARMACEUTICALS, INC. |
| File No. 000-52218 |
Dear Sir or Madam:
We have read Item 4.01 of Form 8-K dated March 7, 2017 of ONCBIOMUNE PHARMACEUTICALS, INC. (“the Registrant”) and are in agreement with the statements contained therein as it pertains to our firm.
We have no basis to agree or disagree with any other statements of the Registrant contained in Item 4.01.
| Sincerely, | |
| /s/ Anton & Chia, LLP |
| Page 1 of 1 |